Bent Stephen, Tiedt Thomas N, Odden Michelle C, Shlipak Michael G
Osher Center for Integrative Medicine at the University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, 111-A1, 4150 Clement Street, San Francisco, California 94121, USA.
Ann Intern Med. 2003 Mar 18;138(6):468-71. doi: 10.7326/0003-4819-138-6-200303180-00010.
Ephedra is widely used in dietary supplements that are marketed to promote weight loss or increase energy; however, the safety of this product has been questioned because of numerous case reports of adverse events.
To compare the risk for adverse events attributable to ephedra and other herbal products.
Comparative case series.
American Association of Poison Control Centers Toxic Event Surveillance System Database Annual Report, 2001.
The relative risk and 95% confidence interval for experiencing an adverse reaction after ephedra use compared with other herbs. This risk was defined as the ratio of adverse reactions to ephedra versus other products, divided by the ratio of their relative use in the United States.
Products containing ephedra accounted for 64% of all adverse reactions to herbs in the United States, yet these products represented only 0.82% of herbal product sales. The relative risks for an adverse reaction in persons using ephedra compared with other herbs were extremely high, ranging from 100 (95% CI, 83 to 140) for kava to 720 (CI, 520 to 1100) for Ginkgo biloba.
Ephedra use is associated with a greatly increased risk for adverse reactions compared with other herbs, and its use should be restricted.
麻黄广泛用于旨在促进减肥或增加能量的膳食补充剂中;然而,由于大量不良事件的病例报告,该产品的安全性受到质疑。
比较麻黄和其他草药产品导致不良事件的风险。
比较病例系列。
美国毒物控制中心协会毒性事件监测系统数据库年度报告,2001年。
与其他草药相比,使用麻黄后发生不良反应的相对风险和95%置信区间。该风险定义为麻黄与其他产品不良反应的比率除以它们在美国的相对使用比率。
含麻黄的产品占美国所有草药不良反应的64%,但这些产品仅占草药产品销售额的0.82%。与其他草药相比,使用麻黄的人发生不良反应的相对风险极高,从卡瓦的100(95%CI,83至140)到银杏的720(CI,520至1100)不等。
与其他草药相比,使用麻黄导致不良反应的风险大大增加,应限制其使用。